Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omega-3 and Oxybutynin for Overactive Bladder
NCT02070042Terminated
- Sponsor
- TriHealth
- Start
- Feb 2014
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of omega-3 fatty acid in overactive bladder (OAB) (2 arms), sponsored by TriHealth. Primary endpoint: Change from baseline in urinary voids per day at 6 weeks. Started Feb 2014; status: terminated.
02
Drugs
omega-3 fatty acid
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT02070042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02070042.